Recent Updates — OCUL

Sanjay Nayak, M.B.B.S., Ph.D., serving as Chief Strategy Officer of Ocular Therapeutix, Inc., notified the company of his resignation on October 14, 2026. His departure is effective October 16, 2026, to assume the role of Chief Executive Officer at a privately held company. The filing does not disclose details regarding a successor or any changes to existing executive compensation arrangements. Ocular Therapeutix develops and commercializes therapies for diseases of the eye.

Ocular Therapeutix reported second quarter 2026 financial results with total net revenue of $13.5 million and a net loss of $(78.8) million, or $(0.35) per share. The company holds $598.6 million in cash as of June 30, 2026, providing runway into 2028. Key business highlights include plans to submit a New Drug Application for AXPAXLI in wet AMD by Q4 2026 following positive FDA alignment. The company also announced amendments to the SOL-R and HELIOS-3 clinical trial protocols to optimize development pathways.

At its 2026 Annual Meeting, Ocular Therapeutix, Inc. stockholders approved an amendment to its 2021 Stock Incentive Plan to increase the number of shares issuable under the plan by 10,000,000 shares. The Board appointed Jason Robins as Chief Financial Officer, whose annual base salary will increase to $535,100 effective July 1, 2026, with a 45% target cash bonus. Ocular Therapeutix, Inc. is a biopharmaceutical company that develops and commercializes ophthalmic therapeutic products.